VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its ...

Merck & Co. has partnered with Variational AI to explore using artificial intelligence in drug discovery. Variational AI CEO Handol Kim says Merck will test Variational’s Enki platform in ...

In life sciences, diffusion models have inspired innovations like MIT’s DiffDock, which predicts how drug molecules will bind to proteins—a critical step in designing new therapies. 3.

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today ...

Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancerVANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE ...

New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies VANCOUVER, British Columbia–(BUSINESS WIRE)–February 20, 2025– Variational AI, the ...

VANCOUVER, British Columbia, February 20, 2025--Compute efficient generative AI foundation model for small molecule drug discovery start-up announces funding from leading AI and biotech investors.